Nephros, Inc. (NEPH)

Nephros, Inc. has experienced several stock events in the past six months. On November 6, 2025, the company reported positive third-quarter 2025 financial results, but the stock declined by 11.5%. On March 12, 2026, Nephros announced its fourth-quarter and record fiscal year 2025 financial results, reporting increased revenue and net income, but gross margin compression due to tariffs led to a stock decline. Over the past 52 weeks, NEPH stock has traded between $6.42 and $1.64, with a share price of $3.93 as of March 11, 2026, representing a 136.75% increase over the previous year.

The available information does not explicitly detail the demand seasonality for Nephros, Inc.'s products and services. Recurring filter use suggests a relatively stable baseline demand, while emergency response sales could introduce variability. The company's focus on infection control and compliance with water quality standards may also suggest a consistent demand driven by regulatory requirements.

Nephros, Inc. is a commercial-stage water technology company specializing in high-performance water filtration solutions for medical and commercial markets. The company operates in the Healthcare sector, focusing on Medical Instruments & Supplies and Surgical & Medical Instruments & Apparatus. Nephros offers FDA-cleared microfilters and ultrafilters for infection control in healthcare facilities, targeting pathogens like Legionella and Pseudomonas. They also provide filters for dialysis water. For commercial applications, Nephros produces filters under the Nephros and AETHER brands to improve water quality by reducing contaminants. Additionally, the company has a Pathogen Detection segment for real-time water quality testing and a Renal Products segment for end-stage renal disease patients.

Nephros, Inc. is headquartered in South Orange, New Jersey, with an additional office in Whippany, New Jersey. The company primarily sells its water filtration products to medical and commercial facilities in the United States. In February 2026, Nephros expanded into the Puerto Rican market, targeting healthcare facilities, foodservice operations, and hospitality businesses, estimating a $10 million market opportunity.

Nephros, Inc. has focused on advancing water quality through innovative filtration technology and water-quality education, launching the Nephros Water Institute in December 2025. The company has reported sustained profitability, achieving its second consecutive year of positive net income in 2025, and has strategically expanded into new markets like Puerto Rico. However, the disclosure of a material weakness in revenue recognition controls and gross margin pressures due to tariffs could negatively impact its reputation.

Nephros, Inc. has 39 institutional owners and shareholders holding a total of 5,305,151 shares. Institutional investors own approximately 41.10% to 47.31% of the company's stock, while insiders own around 2.40% to 11.19%, and public companies and individual investors hold approximately 1.94% to 50.28%. Major institutional shareholders include Wexford Capital LP, Topline Capital Management, LLC, and Vanguard Group Inc. Wexford Capital LP held a significant 34.04% stake as of mid-2025. Lambda Investors LLC is noted as the largest individual shareholder, owning 44.37 million shares.